Pharmacological/pharmaceutical counseling in intensive care medicine
Adequate pharmacotherapy in critically ill patients is challenging for many clinicians. Disease-related pathophysiological changes often lead to complex therapy strategies including many intensive care treatments (e.g. invasive ventilation, renal replacement therapy). These measures often influence drug prescribing and dosing. Therefore, in organ dysfunction such as renal and liver impairment reduced drug elimination has to be considered by adapting drug dosing towards elimination rates. Moreover, as intensive care medicine often includes the use of multiple drugs the risk for drug-drug interactions increases. The current article gives an overview about the complexity of individual pharmacotherapy in intensive care units whilst providing information for its clinical implementation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:116 |
|---|---|
| Enthalten in: |
Medizinische Klinik, Intensivmedizin und Notfallmedizin - 116(2021), 2 vom: 01. März, Seite 173-184 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Die pharmakologische/pharmazeutische Visite in der Intensivmedizin |
|---|
| Beteiligte Personen: |
Hilgarth, H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug incompatibility |
|---|
| Anmerkungen: |
Date Completed 10.03.2021 Date Revised 10.03.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00063-020-00767-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320895866 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320895866 | ||
| 003 | DE-627 | ||
| 005 | 20231226202533.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00063-020-00767-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320895866 | ||
| 035 | |a (NLM)33528630 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Hilgarth, H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological/pharmaceutical counseling in intensive care medicine |
| 246 | 3 | 3 | |a Die pharmakologische/pharmazeutische Visite in der Intensivmedizin |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2021 | ||
| 500 | |a Date Revised 10.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Adequate pharmacotherapy in critically ill patients is challenging for many clinicians. Disease-related pathophysiological changes often lead to complex therapy strategies including many intensive care treatments (e.g. invasive ventilation, renal replacement therapy). These measures often influence drug prescribing and dosing. Therefore, in organ dysfunction such as renal and liver impairment reduced drug elimination has to be considered by adapting drug dosing towards elimination rates. Moreover, as intensive care medicine often includes the use of multiple drugs the risk for drug-drug interactions increases. The current article gives an overview about the complexity of individual pharmacotherapy in intensive care units whilst providing information for its clinical implementation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Drug incompatibility | |
| 650 | 4 | |a Drug interactions | |
| 650 | 4 | |a Hospital pharmacist | |
| 650 | 4 | |a Intensive care | |
| 650 | 4 | |a Renal insufficiency | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Baehr, M |e verfasserin |4 aut | |
| 700 | 1 | |a Kluge, S |e verfasserin |4 aut | |
| 700 | 1 | |a König, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medizinische Klinik, Intensivmedizin und Notfallmedizin |d 2012 |g 116(2021), 2 vom: 01. März, Seite 173-184 |w (DE-627)NLM216019842 |x 2193-6226 |7 nnns |
| 773 | 1 | 8 | |g volume:116 |g year:2021 |g number:2 |g day:01 |g month:03 |g pages:173-184 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00063-020-00767-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 116 |j 2021 |e 2 |b 01 |c 03 |h 173-184 | ||